AI
Sunday, December 22, 2024 10:54:12 AM
LC,
AI Sky knows that the long-committed management are building value. LP is not a stupid Harvard lawyer and she knows what she’s doing to ensure the greatest possible value for her own shares of NWBO stock as well as ours. We can see real evidence of their success if we tune out the bad-faith baseless rumors and instead listen to reliable and relevant current sources such as clinical data collected by world-renowned research institutions, independent peer-reviewers who are qualified oncologists, and government regulators. We might also consider the significance and weight of the independent physicians who are the peer reviewers tasked with deciding whether to award public funding based on the validity and value of the science (NIH and DoD grants).
“The management team is actively building value through strategic initiatives and achievements. Notable examples include:
1. Strategic Acquisitions:
• The acquisition of Flaskworks in 2020 brought advanced, patent-fortified manufacturing technology, EDEN, which facilitates both regulatory support and broad commercialization.
• Another strategic acquisition includes a patent-fortified dendritic cell (DC) technology developed by Roswell Park Comprehensive Cancer Center, further enhancing the company’s IP portfolio.
2. Regulatory and Program Milestones:
• The UK Specials Program, a long-standing initiative, continues with the support of the MHRA, highlighting its ongoing success.
• Regulatory milestones include the MHRA’s approval of the PIP (Pediatric Investigation Plan) and the MIA (Manufacturing and Importation Authorization).
3. Innovative Clinical Trials:
• The company is conducting three ongoing combination therapy trials involving its two novel, patent-fortified DC technologies and PD-1 blockade technology, including Merck’s pembrolizumab. These trials—one at UCLA and two at Roswell Park—are supported by rigorously peer-reviewed grants from the U.S. NIH and U.S. DoD.
• Emerging data from these combination studies demonstrate significant findings.
4. Scientific Validation:
• The publication of significant data in highly respected medical journals, such as JAMA Oncology and Nature Communications, reinforces the credibility and impact of the research.
5. Expert Leadership:
• The recruitment of a world-renowned physician to join NWBO’s Scientific Advisory Board (SAB) underscores the company’s commitment to excellence and innovation.
These achievements collectively demonstrate the management’s strategic vision and their ability to position the company for sustained growth and success.”
⭐️Combo is King!⭐️
https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175564505
AI Sky knows that the long-committed management are building value. LP is not a stupid Harvard lawyer and she knows what she’s doing to ensure the greatest possible value for her own shares of NWBO stock as well as ours. We can see real evidence of their success if we tune out the bad-faith baseless rumors and instead listen to reliable and relevant current sources such as clinical data collected by world-renowned research institutions, independent peer-reviewers who are qualified oncologists, and government regulators. We might also consider the significance and weight of the independent physicians who are the peer reviewers tasked with deciding whether to award public funding based on the validity and value of the science (NIH and DoD grants).
“The management team is actively building value through strategic initiatives and achievements. Notable examples include:
1. Strategic Acquisitions:
• The acquisition of Flaskworks in 2020 brought advanced, patent-fortified manufacturing technology, EDEN, which facilitates both regulatory support and broad commercialization.
• Another strategic acquisition includes a patent-fortified dendritic cell (DC) technology developed by Roswell Park Comprehensive Cancer Center, further enhancing the company’s IP portfolio.
2. Regulatory and Program Milestones:
• The UK Specials Program, a long-standing initiative, continues with the support of the MHRA, highlighting its ongoing success.
• Regulatory milestones include the MHRA’s approval of the PIP (Pediatric Investigation Plan) and the MIA (Manufacturing and Importation Authorization).
3. Innovative Clinical Trials:
• The company is conducting three ongoing combination therapy trials involving its two novel, patent-fortified DC technologies and PD-1 blockade technology, including Merck’s pembrolizumab. These trials—one at UCLA and two at Roswell Park—are supported by rigorously peer-reviewed grants from the U.S. NIH and U.S. DoD.
• Emerging data from these combination studies demonstrate significant findings.
4. Scientific Validation:
• The publication of significant data in highly respected medical journals, such as JAMA Oncology and Nature Communications, reinforces the credibility and impact of the research.
5. Expert Leadership:
• The recruitment of a world-renowned physician to join NWBO’s Scientific Advisory Board (SAB) underscores the company’s commitment to excellence and innovation.
These achievements collectively demonstrate the management’s strategic vision and their ability to position the company for sustained growth and success.”
⭐️Combo is King!⭐️
https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175149927
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175564505
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
